GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas



Status:Recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/10/2019
Start Date:February 27, 2018
End Date:January 5, 2022
Contact:ABTC Operations Office
Email:jfisher@jhmi.edu
Phone:410-955-3657

Use our guide to learn which trials are right for you!

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas

The purpose of this phase I trial is to test the safety of combining GMCI, an
immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care
radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade
gliomas.

Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec
(AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and
stimulate the immune system. Nivolumab is an immune checkpoint inhibitor that may also
stimulate the immune system by blocking the PD-1 immune suppressive pathway. Radiation
therapy uses high energy x-rays to kill tumor cells and shrink tumors and temozolomide is a
chemotherapy drug that kills tumor cells. Giving GMCI, nivolumab, radiation therapy, and
temozolomide may work better in treating patients with high-grade gliomas

PRIMARY OBJECTIVES:

I. To assess the safety/maximum tolerated dose (MTD) of the combination of aglatimagene
besadenovec (AdV-tk) given intra-cranially at the time of initial tumor resection followed by
valacyclovir (GMCI), nivolumab, and standard of care (radiation therapy [RT]+temozolomide
[TMZ]) in patients with high-grade gliomas (HGG).

PRIMARY OBJECTIVES:

I. To assess the safety/maximum tolerated dose (MTD) of the combination of aglatimagene
besadenovec (AdV-tk) given intra-cranially at the time of initial tumor resection followed by
valacyclovir (GMCI), nivolumab, and standard of care (radiation therapy [RT]+temozolomide
[TMZ]) in patients with high-grade gliomas (HGG).

SECONDARY OBJECTIVES:

I. To evaluate safety and toxicity of this combined treatment regimen. II. To estimate
overall survival. III. To estimate progression free survival. IV. Immune biomarkers,
including serum extracellular vesicles (EVs).

OUTLINE:

Patients undergo tumor resection and receive AdV-tk injection into the wall of the resection
cavity. Patients then receive valacyclovir orally three times per day for 14 days. Beginning
on approximately day 8, patients undergo radiation therapy five days per week for 6 weeks.
Temozolomide will be initiated on approximately day 15 after valacyclovir is completed and
will continue until MGMT methylation status is known. If unmethylated, temozolomide will be
discontinued: these patients will constitute Cohort 1. In Cohort 2 - patients with methylated
MGMT - temozolomide will continue. If methylation status is unable to be determined, those
patients will also continue receiving temozolomide (Cohort 2). Both cohorts will receive
nivolumab intravenously every two weeks for up to 52 weeks in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 2 years, and
then every 6 months thereafter.

Inclusion Criteria:

- Patients must have operable brain tumor presumed to be high grade glioma (HGG) based
on clinical and radiologic evaluation, where a gross total surgical resection of the
contrast-enhancing area is intended; pathologic confirmation of HGG must be made at
the time of surgery prior to AdV-tk injection, if not previously determined

- Patients must have a Karnofsky performance status >= 70% (i.e. the patient must be
able to care for himself/herself with occasional help from others)

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (except for
patients with known Gilbert's syndrome who must have normal direct bilirubin)

- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase
(SGOT)/alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =<
3.0 x institutional ULN

- Creatinine =< institutional ULN

- Calculated creatinine clearance >= 40 ml/min (use a modified Cockcroft-Gault equation)

- Activated partial thromboplastin time/partial thromboplastin time (APTT/PTT) =< 1.5 x
institutional ULN

- Patients must be able to provide written informed consent

- Patients must have magnetic resonance imaging (MRI) within 14 days of starting
treatment; patients must be able to tolerate MRI

- Women of childbearing potential must agree to have a negative serum pregnancy test
within 24 hours prior to treatment start; women of childbearing potential must agree
to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry, for the duration of study treatment, and through at
least 5 months after the last dose of study drug; should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately; sexually active men of reproductive potential who are
partners of women with reproductive potential must also agree to use adequate
contraception prior to the study, for the duration of study participation, and through
at least 7 months after the last dose of study drug; adequate methods of effective
birth control include sexual abstinence (men, women); vasectomy; or a condom with
spermicide (men) in combination with barrier methods, hormonal birth control or
intrauterine device (IUD) (women)

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or
bladder; patients with prior malignancies must be disease-free for >= two years;
patients with low-risk prostate cancer on active surveillance are eligible

- Patients must be able to swallow oral medications

- Patients must not have received prior radiation therapy, chemotherapy, immunotherapy
or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense,
peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocyte
[TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for
their brain tumor; glucocorticoid therapy is allowed

Exclusion Criteria:

- Patients receiving any other investigational agents are ineligible

- Patients with a history of hypersensitivity or allergic reactions attributed to
compounds of similar chemical or biologic composition to valacyclovir, acyclovir, or
temozolomide are ineligible; the valacyclovir and temozolomide package inserts can be
referenced for more information

- Patients with a history of severe hypersensitivity reaction to any monoclonal antibody
are ineligible

- Patients who require therapy with systemic immunosuppressive drugs except
corticosteroids are ineligible

- Patients with a history of active autoimmune disease requiring treatment in the past 2
years are ineligible

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, active liver disease or active hepatitis, or psychiatric
illness/social situations that would limit compliance with study requirements, are
ineligible

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with these agents through 1 week after receiving the last dose
of study drugs

- Patients who are known to be human immunodeficiency virus (HIV) positive are
ineligible
We found this trial at
14
sites
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
(336) 716-2011
Principal Investigator: Roy Strowd, MD
Phone: 336-713-6771
Wake Forest University Comprehensive Cancer Center Our newly expanded Comprehensive Cancer Center is the region’s...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Principal Investigator: Cheten cbetteg1@jhmi.edu, MD
Phone: 410-955-4009
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2010 E 90th St
Cleveland, Ohio 44195
(866) 223-8100
Principal Investigator: Manmeet Ahluwalia, MD
Phone: 216-444-7923
Cleveland Clinic Taussig Cancer Center At Taussig Cancer Institute, more than 250 highly skilled doctors,...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
(310) 825-5268
Principal Investigator: Timothy Cloughesy, MD
Phone: 310-825-5321
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Burt Nabors, MD
Phone: 205-934-0309
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Birmingham, Alabama
Principal Investigator: Louis B Nabors, MD
Phone: 205-934-0309
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Elizabeth Gerstner, MD
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Patrick Wen, MD
Phone: 857-307-5286
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Tobias Walbert, MD
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(888) 777-4167
Principal Investigator: Tobias Walbert, MD
Josephine Ford Cancer Center at Henry Ford Hospital A diagnosis of cancer is one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Tom Kaley, MD
Phone: 212-639-5122
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Arati Desai, MD
Phone: 215-615-3673
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Frank Lieberman, MD
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
505 Parnassus Ave
San Francisco, California 94143
(415) 476-1000
Principal Investigator: Susan Chang, MD
Phone: 415-353-2270
University of California, San Francisco Medical Center UCSF Medical Center is recognized throughout the world...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials